GlucoTrack announces start of enrollment for human clinical study of CBGM

Glucotrack (GCTK) has announced the commencement of patient enrollment for its short-term human clinical study. The study will focus on the Company’s continuous blood glucose monitor, CBGM, and will include participants with both type 1 and type 2 diabetes. Data from the study is expected to be available within 6-8 weeks. Unlike traditional continuous glucose monitors that measure glucose levels in interstitial fluid, Glucotrack’s CBGM measures glucose directly from blood, aiming to provide real-time readings without the lag time typically associated with interstitial glucose measurements. The CBGM is a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution.